Shift by Alberta Innovates

Shift talks with Dr. John Lewis about the journey to conquer Covid

January 27, 2021 Dr. John Lewis from Entos Pharmaceutical Season 2 Episode 2
Shift by Alberta Innovates
Shift talks with Dr. John Lewis about the journey to conquer Covid
Chapters
Shift by Alberta Innovates
Shift talks with Dr. John Lewis about the journey to conquer Covid
Jan 27, 2021 Season 2 Episode 2
Dr. John Lewis from Entos Pharmaceutical

Welcome to Shift by Alberta Innovates.

On this episode we speak with Dr. John Lewis from Edmonton-based ENTOS pharmaceuticals about their journey toward creating a made-in-Alberta vaccine for Covid-19.

John walks us through how he and his team's work on genetic medications as a treatment for metastatic cancer created an opportunity to develop a potential Covid vaccine using their proprietary Fusogenix genetic medicines delivery platform.

Along the way we discuss the steps within a clinical trial, how researchers from "competing" labs work together for everyone's benefit,  the implications of the much used phrase "fast tracking" when it comes to the development of medical interventions, his work on something called tumor glue, and much more.

But don't our word for it. Grab seat, click play and learn more about the Journey to Conquer Covid.

BIO

John D. Lewis, Ph.D, founder, Chief Executive Officer of Entos Pharmaceuticals
 
John is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta in Edmonton, Alberta.

A scientist and serial entrepreneur, his research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer.

He has pioneered the use of intravital imaging to discover key therapeutic targets in cancer.

Show Notes

Welcome to Shift by Alberta Innovates.

On this episode we speak with Dr. John Lewis from Edmonton-based ENTOS pharmaceuticals about their journey toward creating a made-in-Alberta vaccine for Covid-19.

John walks us through how he and his team's work on genetic medications as a treatment for metastatic cancer created an opportunity to develop a potential Covid vaccine using their proprietary Fusogenix genetic medicines delivery platform.

Along the way we discuss the steps within a clinical trial, how researchers from "competing" labs work together for everyone's benefit,  the implications of the much used phrase "fast tracking" when it comes to the development of medical interventions, his work on something called tumor glue, and much more.

But don't our word for it. Grab seat, click play and learn more about the Journey to Conquer Covid.

BIO

John D. Lewis, Ph.D, founder, Chief Executive Officer of Entos Pharmaceuticals
 
John is the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta in Edmonton, Alberta.

A scientist and serial entrepreneur, his research interests lie in the areas of nanotechnology and imaging as they relate to the development of novel treatments for chronic diseases such as aging and cancer.

He has pioneered the use of intravital imaging to discover key therapeutic targets in cancer.